Hong Wu, Lianxin Liu, Sulai Liu, Xiaoli Chai, Jie Qiu, Yanqiao Zhang, Yu Zhang, Guicheng Wu, Yongyi Zeng, Junye Wang, Yong Zha, Bing Huang, Feixiang Wu, Jun Zheng, Yinghua Lan, Binhua Lv, Liqing Wu, Ruirui Xu, Anlan Zhang, Andrew X. Zhu. "Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4014